RESEARCH TRIANGLE PARK, N.C. – April 7, 2009 – Quintiles Transnational Corp. today announced the appointment of Richard (Rich) Pilnik to serve as President, Innovex – a Quintiles company that helps pharmaceutical and biotech companies maximize commercial success across a product’s lifecycle.

Pilnik has 25 years of experience in the pharmaceutical commercial sector, most recently as Group Vice President and Chief Marketing Officer at Lilly’s Indianapolis headquarters in the United States. He has a comprehensive and thorough understanding of the global commercial landscape, beginning his career as a sales representative in the U.S. before serving in increasingly senior leadership roles in Venezuela, Brazil, Mexico and Europe. He is fluent in English, Portuguese and Spanish. Pilnik earned his bachelor of arts from Duke University and his masters in business administration from the Kellogg School of Business, Northwestern University.

“With Rich’s experience in addressing complex business opportunities and challenges across many countries, together with the experience and expertise we already have, Innovex is poised to expand its visibility and leadership in the commercial arena,” said Quintiles Transnational Chairman and CEO Dennis Gillings, CBE.

Pilnik said: “Innovex is already recognized for its outstanding customer service and insight in providing flexible, effective solutions to meet commercial challenges. As the commercial landscape continues to evolve at an unprecedented pace, Innovex is well-positioned to develop further a full range of multi-country solutions to help our customers navigate, and be successful in, the new commercial world.”

Innovex has approximately 7,500 professionals deployed across 17 markets, selling and supporting brands in various therapeutic areas in both primary and secondary care.

Quintiles Transnational Corp. helps bring new medicines to market and peak sales faster by providing innovative, high-quality development, financial and commercialization solutions to the pharmaceutical and biotechnology industries. With more than 22,000 employees and offices in more than 50 countries, Quintiles is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at